TEL AVIV, Israel, Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-15, 2023.
Investors may view the Chemomab presentation online beginning on September 11, 2023, at 7:00 AM ET via the following link: https://journey.ct.events/view/cfe7b944-a4a2-444a-97d8-702be00cac82.
This link will remain active for 90 days. It will also be available at the investor section of the Chemomab website at https://investors.chemomab.com/events.
Chemomab senior management will be available for virtual one-on-one meetings with investors during the conference from September 11 through September 14, 2023. For information about the conference and to register to meet with Chemomab management, visit https://hcwevents.com/annualconference/.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 2 liver fibrosis trial and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with topline data expected in the second half of 2024. For more information about Chemomab, visit chemomab.com.
Contact:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor &
Public Relations, Strategic Communications
Phone: +1 917-355-9234
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.11 |
| Daily Change: | -0.05 -4.31 |
| Daily Volume: | 42,084 |
| Market Cap: | US$20.930M |
March 06, 2025 March 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
